Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study

Sponsor
Boehringer Ingelheim
Study ID
NCT07743996
Status
Recruiting
Apply to this trial

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.

Key Dates

First listed
Aug 4, 2026
Start date
Aug 1, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Japanese patients with IPF/PPF

Primary Outcome Measure

Mean (95% CI) scores for the PESaM side effects sub-domain in the overall population [ Time Frame: Assessed once at survey completion (approximately 20 minutes after survey initiation). ]

Central Contacts

Related Studies